Siponimod: A Review in Secondary Progressive Multiple Sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Secondary progressive multiple sclerosis (SPMS) is a debilitating neurological condition with limited treatment options.
• Sphingosine 1-phosphate receptor (S1PR) modulators represent a class of therapies targeting immune cell trafficking.

Purpose of the Study:

• To evaluate the efficacy and safety of oral siponimod in patients with SPMS.
• To assess the long-term effects of siponimod treatment in an open-label extension study.

Main Methods:

• The pivotal EXPAND trial involved a broad spectrum of SPMS patients treated with once-daily oral siponimod 2 mg.
• Efficacy was measured by clinical and MRI-defined outcomes, including 3-month confirmed disability progression on the Expanded Disability Status Scale (EDSS).
• Safety was monitored throughout the double-blind core phase and the open-label extension phase (up to 5 years).

Main Results:

• Siponimod significantly reduced clinical and MRI-defined outcomes of disease activity and disability progression compared to placebo.
• Beneficial effects were sustained during long-term treatment in the open-label extension phase.
• The safety profile was generally well-tolerated, consistent with other S1PR modulators, with no new safety signals identified.

Conclusions:

• Oral siponimod is an effective treatment for active SPMS, demonstrating sustained efficacy and a favorable safety profile.
• Siponimod offers a convenient oral dosage regimen and represents an important therapeutic option for adult patients with SPMS.
• Further real-world data will help define the long-term role of siponimod in SPMS management.